Revenue Growth Leaders
GYRE is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
GYRE THERAPEUTICS INC (GYRE) Stock Price & Overview
NASDAQ:GYRE • US4037831033
Current stock price
7.87 USD
-0.07 (-0.88%)
At close:
7.86 USD
-0.01 (-0.13%)
After Hours:
The current stock price of GYRE is 7.87 USD. Today GYRE is down by -0.88%. In the past month the price increased by 11.79%. In the past year, price decreased by -13.23%.
GYRE Key Statistics
52-Week Range6.57 - 11.78
Current GYRE stock price positioned within its 52-week range.
1-Month Range6.77 - 8.2
Current GYRE stock price positioned within its 1-month range.
- Market Cap
- 718.61M
- P/E
- 43.72
- Fwd P/E
- N/A
- EPS (TTM)
- 0.18
- Dividend Yield
- N/A
GYRE Stock Performance
Today
-0.88%
1 Week
+0.38%
1 Month
+11.79%
3 Months
+0.25%
Longer-term
6 Months -3.67%
1 Year -13.23%
2 Years -49.55%
3 Years N/A
5 Years N/A
10 Years N/A
GYRE Stock Chart
GYRE Stock Screens
GYRE currently appears in the following ChartMill screener lists.
GYRE Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to GYRE. When comparing the yearly performance of all stocks, GYRE is a bad performer in the overall market: 77.72% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
GYRE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to GYRE. GYRE has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GYRE Earnings
On March 12, 2026 GYRE reported an EPS of 0.05 and a revenue of 37.20M. The company missed EPS expectations (-13.5% surprise) and beat revenue expectations (2.9% surprise).
Next Earnings DateMay 8, 2026
Last Earnings DateMar 12, 2026
PeriodQ4 / 2025
EPS Reported$0.05
Revenue Reported37.195M
EPS Surprise -13.50%
Revenue Surprise 2.90%
GYRE Forecast & Estimates
9 analysts have analysed GYRE and the average price target is 19.04 USD. This implies a price increase of 141.93% is expected in the next year compared to the current price of 7.87.
For the next year, analysts expect an EPS growth of -281.33% and a revenue growth 19.33% for GYRE
Analysts
Analysts84.44
Price Target19.04 (141.93%)
EPS Next Y-281.33%
Revenue Next Year19.33%
GYRE Groups
Sector & Classification
GYRE Financial Highlights
Over the last trailing twelve months GYRE reported a non-GAAP Earnings per Share(EPS) of 0.18. The EPS decreased by -60.74% compared to the year before.
Income Statements
Revenue(TTM)116.59M
Net Income(TTM)5.03M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 4.31% | ||
| ROA | 3.03% | ||
| ROE | 4.74% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%4447.83%
Sales Q2Q%33.45%
EPS 1Y (TTM)-60.74%
Revenue 1Y (TTM)10.24%
GYRE Ownership
Ownership
Inst Owners3.69%
Shares91.31M
Float12.15M
Ins Owners7%
Short Float %12.56%
Short Ratio14.65
GYRE Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.83 | 362.808B | ||
| AMGN | AMGEN INC | 15.1 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 15.08 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.42 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.94 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.19 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.53 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GYRE
Company Profile
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Company Info
IPO: 2006-04-12
GYRE THERAPEUTICS INC
12770 High Bluff Drive, Suite 150
San Diego CALIFORNIA US
Employees: 625
Phone: 18585677770
GYRE THERAPEUTICS INC / GYRE FAQ
What does GYRE do?
Gyre Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in San Diego, California and currently employs 618 full-time employees. The company went IPO on 2006-04-12. The firm is focused on the development and commercialization of F351 (Hydronidone) for the treatment of MASH-associated fibrosis in the United States. The company is also advancing a diverse pipeline in the PRC through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. F351 is a structural derivative of ETUARY. F573 is its clinical-stage product candidate for the treatment of acute/acute-on-chronic liver failure (ALF/ACLF) in Phase 2 clinical trials in the PRC. F528 is a preclinical-stage candidate targeting chronic obstructive pulmonary disease. F230 is a clinical-stage compound for the treatment of pulmonary arterial hypertension. The company is focused on commercializing therapies for the treatment of pulmonary fibrosis through its two therapeutic products: ETUARY (pirfenidone) and nintedanib. The company is also focused on commercializing the avatrombopag product.
Can you provide the latest stock price for GYRE THERAPEUTICS INC?
The current stock price of GYRE is 7.87 USD. The price decreased by -0.88% in the last trading session.
Does GYRE stock pay dividends?
GYRE does not pay a dividend.
What is the ChartMill rating of GYRE THERAPEUTICS INC stock?
GYRE has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
What do analysts say about GYRE THERAPEUTICS INC (GYRE) stock?
9 analysts have analysed GYRE and the average price target is 19.04 USD. This implies a price increase of 141.93% is expected in the next year compared to the current price of 7.87.
Can you provide the market cap for GYRE THERAPEUTICS INC?
GYRE THERAPEUTICS INC (GYRE) has a market capitalization of 718.61M USD. This makes GYRE a Small Cap stock.
What is the ownership structure of GYRE THERAPEUTICS INC (GYRE)?
You can find the ownership structure of GYRE THERAPEUTICS INC (GYRE) on the Ownership tab.